Murphy, Middleton, Hinkle & Parker, Inc. Amgen Inc Transaction History

Murphy, Middleton, Hinkle & Parker, Inc.

$172 Million
Q1 2024

A detailed history of Murphy, Middleton, Hinkle & Parker, Inc. transactions in Amgen Inc stock. As of the latest transaction made, Murphy, Middleton, Hinkle & Parker, Inc. holds 3,749 shares of AMGN stock, worth $1.17 Million. This represents 0.62% of its overall portfolio holdings.

Number of Shares

3,749

Previous 3,749 -0.0%

Holding current value

$1.17 Million

Previous $1.08 Million 1.3%

% of portfolio

0.62%

Previous 0.67%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 24, 2024	SELL	$255.7 - $288.46 $767 - $865	-3 Reduced 0.08%	3,749 $1.08 Million
Q3 2023 Oct 03, 2023	SELL	$218.65 - $271.46 $41,543 - $51,577	-190 Reduced 4.82%	3,752 $1.01 Million
Q4 2022 Jan 17, 2023	SELL	$229.03 - $291.01 $8,016 - $10,185	-35 Reduced 0.88%	3,942 $1.04 Million
Q3 2022 Oct 07, 2022	SELL	$224.46 - $253.15 $24,690 - $27,846	-110 Reduced 2.69%	3,977 $896,000
Q3 2021 Oct 07, 2021	SELL	$212.27 - $248.7 $849 - $994	-4 Reduced 0.1%	4,087 $869,000

Q2 2021 Jul 13, 2021	BUY	$233.58 - $259.14 $8,642 - $9,588	37 Added 0.91%	4,091 $997,000
Q1 2021 Apr 08, 2021	SELL	$221.91 - $258.6 $7,101 - $8,275	-32 Reduced 0.78%	4,054 $1.01 Million
Q4 2020 Jan 12, 2021	SELL	$216.38 - $257.67 $25,100 - $29,889	-116 Reduced 2.76%	4,086 $939,000
Q3 2020 Oct 13, 2020	SELL	$234.65 - $260.95 $41,533 - $46,188	-177 Reduced 4.04%	4,202 $1.07 Million
Q1 2019 Apr 17, 2019	SELL	$180.87 - $203.88 $7,777 - $8,766	-43 Reduced 0.97%	4,379 $832,000
Q2 2018 Jul 13, 2018	BUY	$166.05 - $186.51 $734,273 - $824,747	4,422 New	4,422 $816,000

Others Institutions Holding AMGN

# of Institutions

2,933

Shares Held

401M

Call Options Held

6.59M

Put Options Held

6.6M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $166B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Murphy, Middleton, Hinkle & Parker, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Murphy, Middleton, Hinkle & Parker, Inc. with notifications on news.

Account

Murphy, Middleton, Hinkle & Parker, Inc. Amgen Inc Transaction History